相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis
Omid Kiani Ghalesardi et al.
LEUKEMIA RESEARCH (2021)
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Ilaria S. Pagani et al.
LEUKEMIA (2020)
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors
Mariella D'Adda et al.
CANCER (2019)
Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay
Lasse Kjaer et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key?
Simona Bernardi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type
Michele Baccarani et al.
LEUKEMIA (2019)
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
Michele Baccarani et al.
LEUKEMIA (2019)
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Juan Carlos Hernandez-Boluda et al.
BLOOD CANCER JOURNAL (2018)
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Frederic Millot et al.
HAEMATOLOGICA (2017)
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
Massimo Breccia et al.
Oncotarget (2017)
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Frederic Millot et al.
HAEMATOLOGICA (2017)
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
Katia Borgia Barbosa Pagnano et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib
Fausto Castagnetti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors
Amy Hughes et al.
BLOOD (2017)
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
Han-Xin Lin et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
Preetesh Jain et al.
BLOOD (2016)
A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)
Silvia Marce et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2015)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Benjamin Hanfstein et al.
HAEMATOLOGICA (2014)
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
B. Hanfstein et al.
LEUKEMIA (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
Joerg Hasford et al.
BLOOD (2011)
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
Xin An et al.
LEUKEMIA RESEARCH (2010)
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
Alfonso Quintas-Cardama et al.
BLOOD (2009)
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
Claire M. Lucas et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts
S. Polampalli et al.
GENETICS AND MOLECULAR RESEARCH (2008)
The molecular biology of chronic myeloid leukemia
MWN Deininger et al.
BLOOD (2000)
The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia
RA Perego et al.
EUROPEAN JOURNAL OF CANCER (2000)
分享论文
